Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Palisade Bio Inc PALI
$1.45
▼ -7.64%
($-0.12)
⬇️ Below Yest. Low
Open
$1.57
Prev Close
$1.57
Day Range
$1.45 – $1.59
52W Range
$0.64 – $2.86
Market Cap
$252.69M
Beta
1.52
EPS (TTM)
$-0.64
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-12-20 |
| Shares Out. | 173,580,000 |
| Website | palisadebio.com/ ↗ |
| Phone | 13026974590 |
| Employees | 14 |
| Revenue | $500,000 |
| Gross Profit | $500,000 |
| Net Income | -$10.6M |
| Free Cash Flow | -$18.2M |
| Total Assets | $127.3M |
| Total Liabilities | $5.6M |
| Equity | $121.7M |
About Palisade Bio Inc
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Palisade Bio Inc is a publicly traded company under the ticker symbol PALI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)
📰 Latest News for PALI
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript